Penbrook Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Penbrook Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$489K	Hold	785	–	–	0.31%	65
2026 Q1	$607K	Sell	785 -12	-2%	-$9.19K	0.46%	54
2025 Q4	$615K	Hold	797	–	–	0.42%	54
2025 Q3	$448K	Hold	797	–	–	0.31%	62
2025 Q2	$418K	Sell	797 -100	-11%	-$55.8K	0.31%	61
2025 Q1	$569K	Hold	897	–	–	0.43%	52
2024 Q4	$639K	Sell	897 -250	-22%	-$210K	0.44%	49
2024 Q3	$1.21M	Hold	1,147	–	–	0.78%	28
2024 Q2	$1.21M	Hold	1,147	–	–	0.74%	28
2024 Q1	$1.1M	Hold	1,147	–	–	0.68%	32
2023 Q4	$1.01M	Buy	1,147 +100	+10%	+$82.3K	0.68%	33
2023 Q3	$862K	Buy	1,047 +25	+2%	+$19.6K	0.63%	38
2023 Q2	$734K	Sell	1,022 -50	-5%	-$38.5K	0.53%	44
2023 Q1	$881K	Hold	1,072	–	–	0.67%	41
2022 Q4	$773K	Sell	1,072 -200	-16%	-$148K	0.66%	43
2022 Q3	$876K	Hold	1,272	–	–	0.75%	36
2022 Q2	$752K	Hold	1,272	–	–	0.59%	51
2022 Q1	$888K	Hold	1,272	–	–	0.58%	54
2021 Q4	$803K	Hold	1,272	–	–	0.48%	62
2021 Q3	$770K	Hold	1,272	–	–	0.48%	64
2021 Q2	$710K	Buy	1,272 +462	+57%	+$234K	0.43%	65
2021 Q1	$383K	Buy	+810	New	+$394K	0.28%	82

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Penbrook Management's REGN Position: Q2 2026 in Review

Penbrook Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 785 shares worth $489K. The position accounts for 0.31% of the portfolio, ranked #65.

Penbrook Management first reported a position in REGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.21M in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Penbrook Management held 785 shares of Regeneron Pharmaceuticals worth $489K as of Q2 2026.
Penbrook Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.31% of Penbrook Management's portfolio in Q2 2026, its #65 holding.
Penbrook Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Penbrook Management's Regeneron Pharmaceuticals position peaked at $1.21M in Q3 2024.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Penbrook Management's 13F filing for Q2 2026, filed 23 Jul 2026.